JWJing-Feng Wang

Jing-Feng Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jing-Feng Wang has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Altered serum levels of IL-33 in patients with advanced systolic chronic heart failure: correlation with oxidative stress

    by Hai-Feng Zhang, Shuang-Lun Xie, Yang-Xin Chen, Jing-Ting Mai, Jing-Feng Wang, Wa-Li Zhu, Li-Guang Zhu

    Interleukin-33 (IL-33) has been linked to chronic heart failure (CHF) in animal studies, but data on serum IL-33 levels in human CHF are not available. We analyzed levels of IL-33 in serum, and investigated the possible role of IL-33 in oxidative stress.


  • Complement factor H Y402H gene polymorphism and coronary heart disease susceptibility: a meta-analysis

    by Hai-Feng Zhang, Jing-Feng Wang, Yan Wang, Li-Guang Zhu, Lei Lei

    The complement factor H (CFH) Y402H (T1277C) gene polymorphism has been reported to be associated with coronary heart disease (CHD), but results were conflicting. To evaluate the role of the variant in CHD, we performed meta-analyses of all available data. Both electronic and manual searches were performed, all relevant studies were identified. ORs with 95% confidential intervals (CI) under codominant (CC versus TT, TC versus TT), dominant (CC + TC versus TT) and recessive (CC versus TT + TC) models were calculated. Publication bias was addressed. Ten studies including 11 cohorts comprising of 29,764 participants were included. No association between the CFH T1227C polymorphism and CHD could be found. (For overall analysis: dominant model, OR = 1.04, 95%CI: 0.97–1.11; recessive model, OR = 1.04, 95%CI: 0.97–1.11; for Caucasian subgroup: OR = 1.08 95%CI: 0.92–1.27; recessive model, OR = 1.03, 95%CI: 0.96–1.11). Two studies reported positive results in separate population (Caucasian study: recessive model, OR = 0.51, 95%CI: 0.30–0.86; Asians study: dominant model, OR = 2.37, 95%CI: 1.13–4.96). Current evidence do not support the association between the CFH T1277C polymorphism and CHD risk among common population. The association, which could be influenced by CHD onset age, CHD risk factors status and genetics backgrounds, might be significant in some population. More studies on different CHD onset ages and risk factor status should be encouraged.